<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181803</url>
  </required_header>
  <id_info>
    <org_study_id>8189-003</org_study_id>
    <nct_id>NCT02181803</nct_id>
  </id_info>
  <brief_title>MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)</brief_title>
  <official_title>A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 3-part dose titration study will assess MK-8189 safety, tolerability, pharmacokinetics
      (PK), and central nervous system activity. Part 1 (Panels A and B) will assess MK-8189
      administered as monotherapy in participants with schizophrenia. Part 2 (Panel C) will assess
      MK-8189 administered as add-on to atypical antipsychotic treatment in participants with
      schizophrenia. Part 3 (Panel D) will assess monotherapy with MK-8189 in healthy participants,
      including those of Japanese descent. The primary hypothesis is that there is at least one
      dose of MK-8189 that is generally safe and well-tolerated which will have the desired PK
      parameters in participants with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As specified by Phase 1 protocol-flexible language in the protocol, modifications to the dose
      or dosing regimen can be made to achieve the scientific goals of the trial objectives and/or
      ensure appropriate safety of the trial participants. The proposed doses for each Part may be
      adjusted downward based on evaluation of safety, tolerability, and pharmacokinetic data
      observed in previous panels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2014</start_date>
  <completion_date type="Actual">April 23, 2015</completion_date>
  <primary_completion_date type="Actual">April 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants</measure>
    <time_frame>Day 1, 4, 8, 11 and 14 pre-dose and 24 hours post-dose</time_frame>
    <description>C24hr was defined as the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189. In participants receiving MK-8189, blood samples were collected pre-dose and 24 hours post-dose to estimate C24hr following MK-8189 administration. As specified by the protocol, C24hr was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from C24 analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC[0-24hr]) of MK-8189 in Schizophrenia Participants</measure>
    <time_frame>Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>AUC was defined as a measure of MK-8189 exposure that was calculated as the product of plasma drug concentration and time. The linear-up-log down rule was used to estimate AUC. Blood samples were collected pre-dose and up to 24 hours post-dose to estimate AUC(0-24hr) following MK-8189 administration. As specified by the protocol, AUC(0-24hr) was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from AUC(0-24hr) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189 in Schizophrenia Participants</measure>
    <time_frame>Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose</time_frame>
    <description>Cmax was defined as the maximum concentration of MK-8189 observed in plasma. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Cmax following MK-8189 administration. As specified by the protocol, Cmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Cmax analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Post-dose at Which the Maximum Plasma Concentration (Tmax) of MK-8189 Was Observed in Schizophrenia Participants</measure>
    <time_frame>Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose</time_frame>
    <description>Tmax was defined as the time required post dose to reach a maximum plasma concentration of MK-8189. It was estimated as the actual sampling time at the highest MK-8189 plasma concentration. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Tmax following MK-8189 administration. As specified by the protocol, Tmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Tmax analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent t1/2) in Schizophrenia Participants on Day 14</measure>
    <time_frame>Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose</time_frame>
    <description>t1/2 was defined as the time required to divide the MK-8189 plasma concentration by half after reaching pseudo-equilibrium. At least three quantifiable post-Cmax, terminal phase concentrations collected were used to calculate the apparent t1/2. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points on Day 14 to estimate t1/2 following MK-8189 administration. As specified by the protocol, t1/2 was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, the Day 14 timepoint was not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from t1/2 analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced at least one AE were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue From Study Treatment Due to an AE</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 13 in Mismatched Negativity (MMN) Peak Amplitude in Monotherapy MK-8189-treated Schizophrenia Participants</measure>
    <time_frame>Baseline and Day 13</time_frame>
    <description>MMN is a response to deviant tone (stimuli) measured in electroencephalogram (EEG) signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; this difference at peak waveform is MMN peak amplitude. Schizophrenic participants show reduced response to deviant stimuli. Peak amplitude change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 13 in Mismatched Negativity (MMN) Area Under Curve (AUC) in Monotherapy MK-8189-treated Schizophrenia Participants</measure>
    <time_frame>Baseline and Day 13</time_frame>
    <description>MMN is a response to deviant tone (stimuli) measured in EEG signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; AUC was measured as the product of MMN amplitude and time. Schizophrenic participants show reduced response to deviant stimuli. AUC change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-40 mg: Schizophrenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Panel D Placebo Monotherapy: Healthy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants will receive dose-matched placebo to MK-8189 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8189</intervention_name>
    <description>MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg</description>
    <arm_group_label>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-40 mg: Schizophrenic</arm_group_label>
    <arm_group_label>Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic</arm_group_label>
    <arm_group_label>Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic</arm_group_label>
    <arm_group_label>Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD</description>
    <arm_group_label>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</arm_group_label>
    <arm_group_label>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</arm_group_label>
    <arm_group_label>Part 3 Panel D Placebo Monotherapy: Healthy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Base Monotherapy</intervention_name>
    <description>For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.</description>
    <arm_group_label>Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic</arm_group_label>
    <arm_group_label>Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic</arm_group_label>
    <arm_group_label>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        INCLUSION CRITERIA FOR SCHIZOPHRENIA PARTICIPANTS

          -  Male or non-pregnant and non-breast feeding female. If participant is male with a
             female partner of child-bearing potential, participant must agree to use a medically
             acceptable method of contraception during the trial and for 120 days after the last
             dose of trial drug. If their partner is pregnant, males must agree to use a condom

          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 40 kg/m^2

          -  Meet diagnostic criteria for schizophrenia or schizoaffective disorder according to
             the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria with the
             onset of the first episode being no less than 2 years prior to study entry

          -  Be in the non-acute phase of illness and clinically stable for 3 months prior to
             screening

          -  History of receiving and tolerating antipsychotic medication within the usual dose
             range employed for schizophrenia

          -  Participants with hypothyroidism, diabetes, high blood pressure, chronic respiratory
             conditions or other mild forms of these medical conditions could be considered as
             candidates for study enrollment if their condition is stable and the prescribed dose
             and regimen of medication is stable for at least 3 months prior to screening and there
             are no expected changes in comedication during the study

          -  Has a negative urinary drug screen at screening

        INCLUSION CRITERIA FOR HEALTHY PARTICIPANTS

          -  Male, or non-pregnant and non-breast feeding female of Japanese or non-Japanese
             descent. If participant is male with a female partner of child-bearing potential,
             participant must agree to use a medically acceptable method of contraception during
             the trial and for 120 days after the last dose of trial drug. If their partner is
             pregnant, males must agree to use a condom

          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 35 kg/m^2

          -  In good health

          -  Nonsmoker and/or has not used nicotine or nicotine-containing products (e.g., nicotine
             patch) for at least approximately 3 months

          -  Has a negative urinary drug screen at screening

        Exclusion Criteria:

        EXCLUSION CRITERIA FOR SCHIZOPHRENIA PARTICIPANTS

          -  DSM-IV axis I psychiatric diagnosis other than schizophrenia or schizoaffective
             disorder within one month of screening

          -  Has evidence or history of mental retardation, borderline personality disorder,
             anxiety disorder, or organic brain syndrome

          -  History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia

          -  Untreated or uncompensated clinically significant renal, endocrine, hepatic,
             respiratory, gastrointestinal, psychiatric, neurologic, cardiovascular, hematological,
             immunological or cerebrovascular disease, malignance, allergic disease or other
             chronic and/or degenerative process at screening

          -  Has a history of cancer (malignancy) with certain exceptions

          -  Treatment with clozapine for schizophrenia or treatment with monoamine oxidase
             inhibitors within 3 months of screening

          -  Received a parenteral depot antipsychotic medication within 3 months of screening

          -  Participated in another investigational study within 4 weeks, prior to screening

        EXCLUSION CRITERIA FOR HEALTHY PARTICIPANTS

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular
             (including hypertension, angina, coronary artery disease, valvular disease, heart rate
             or rhythm abnormalities), hematological, hepatic, immunological, renal, respiratory,
             genitourinary or major neurological (including stroke and chronic seizures)
             abnormalities or diseases

          -  Mentally or legally incapacitated

          -  History of clinically diagnosed depression, anxiety disorder, or any history of
             psychiatric disorders having required drug treatment or hospitalization

          -  History of cancer (malignancy)

          -  Unable to refrain from or anticipates the use of any medication, including
             prescription and non-prescription drugs or herbal remedies throughout the trial

          -  Participated in another investigational study within 4 weeks, prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2014</study_first_posted>
  <results_first_submitted>March 12, 2020</results_first_submitted>
  <results_first_submitted_qc>March 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Forty-three schizophrenia participants and 12 healthy volunteers were randomized to either MK-8189 or placebo in Part 1 Panels A &amp; B, Part 2 Panel C, or Part 3 Panel D. MK-8189 dose and schedule were modified for participants based on tolerability.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-4 mg: Schizophrenic</title>
          <description>Participant with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg once daily (QD) Days 1-4 and 4 mg QD Days 5-14</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-12 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
          <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
        </group>
        <group group_id="P4">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
        </group>
        <group group_id="P5">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14</description>
        </group>
        <group group_id="P6">
          <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
          <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
        </group>
        <group group_id="P7">
          <title>Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy</title>
          <description>Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
        </group>
        <group group_id="P8">
          <title>Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy</title>
          <description>Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14</description>
        </group>
        <group group_id="P9">
          <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
          <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-4 mg: Schizophrenic</title>
          <description>Participant with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg once daily (QD) Days 1-4 and 4 mg QD Days 5-14</description>
        </group>
        <group group_id="B2">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-12 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
          <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
        </group>
        <group group_id="B4">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
        </group>
        <group group_id="B5">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14</description>
        </group>
        <group group_id="B6">
          <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
          <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
        </group>
        <group group_id="B7">
          <title>Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy</title>
          <description>Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
        </group>
        <group group_id="B8">
          <title>Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy</title>
          <description>Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14</description>
        </group>
        <group group_id="B9">
          <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
          <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="1"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="B2" value="44.2" spread="8.7"/>
                    <measurement group_id="B3" value="44.0" spread="9.0"/>
                    <measurement group_id="B4" value="43.8" spread="8.9"/>
                    <measurement group_id="B5" value="41.7" spread="14.7"/>
                    <measurement group_id="B6" value="44.5" spread="7.6"/>
                    <measurement group_id="B7" value="43.3" spread="8.7"/>
                    <measurement group_id="B8" value="55.0" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="B9" value="43.0" spread="5.7"/>
                    <measurement group_id="B10" value="43.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants</title>
        <description>C24hr was defined as the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189. In participants receiving MK-8189, blood samples were collected pre-dose and 24 hours post-dose to estimate C24hr following MK-8189 administration. As specified by the protocol, C24hr was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from C24 analysis.</description>
        <time_frame>Day 1, 4, 8, 11 and 14 pre-dose and 24 hours post-dose</time_frame>
        <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had C24 data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants</title>
          <description>C24hr was defined as the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189. In participants receiving MK-8189, blood samples were collected pre-dose and 24 hours post-dose to estimate C24hr following MK-8189 administration. As specified by the protocol, C24hr was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from C24 analysis.</description>
          <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had C24 data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="31.7"/>
                    <measurement group_id="O6" value="60.5" spread="37.1"/>
                    <measurement group_id="O7" value="161" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="94.8"/>
                    <measurement group_id="O6" value="80.9" spread="49.1"/>
                    <measurement group_id="O7" value="242" spread="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="183" spread="52.2"/>
                    <measurement group_id="O7" value="174" spread="39.4"/>
                    <measurement group_id="O8" value="419" spread="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="148" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O3" value="387" spread="42.0"/>
                    <measurement group_id="O8" value="321" spread="45.1"/>
                    <measurement group_id="O9" value="563" spread="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="11"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="149" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O4" value="459" spread="33.3"/>
                    <measurement group_id="O9" value="517" spread="52.0"/>
                    <measurement group_id="O10" value="655" spread="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC[0-24hr]) of MK-8189 in Schizophrenia Participants</title>
        <description>AUC was defined as a measure of MK-8189 exposure that was calculated as the product of plasma drug concentration and time. The linear-up-log down rule was used to estimate AUC. Blood samples were collected pre-dose and up to 24 hours post-dose to estimate AUC(0-24hr) following MK-8189 administration. As specified by the protocol, AUC(0-24hr) was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from AUC(0-24hr) analysis.</description>
        <time_frame>Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had AUC(0-24hr) data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC[0-24hr]) of MK-8189 in Schizophrenia Participants</title>
          <description>AUC was defined as a measure of MK-8189 exposure that was calculated as the product of plasma drug concentration and time. The linear-up-log down rule was used to estimate AUC. Blood samples were collected pre-dose and up to 24 hours post-dose to estimate AUC(0-24hr) following MK-8189 administration. As specified by the protocol, AUC(0-24hr) was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from AUC(0-24hr) analysis.</description>
          <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had AUC(0-24hr) data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
          <units>nM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090" spread="29.8"/>
                    <measurement group_id="O6" value="1040" spread="27.3"/>
                    <measurement group_id="O7" value="2600" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2160" spread="69.6"/>
                    <measurement group_id="O6" value="1810" spread="42.7"/>
                    <measurement group_id="O7" value="5740" spread="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4390" spread="54.4"/>
                    <measurement group_id="O7" value="4300" spread="31.5"/>
                    <measurement group_id="O8" value="10500" spread="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4720" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O3" value="9770" spread="40.8"/>
                    <measurement group_id="O8" value="8540" spread="31.2"/>
                    <measurement group_id="O9" value="14900" spread="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="11"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4100" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O4" value="12300" spread="27.0"/>
                    <measurement group_id="O9" value="13200" spread="38.5"/>
                    <measurement group_id="O10" value="18700" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189 in Schizophrenia Participants</title>
        <description>Cmax was defined as the maximum concentration of MK-8189 observed in plasma. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Cmax following MK-8189 administration. As specified by the protocol, Cmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Cmax analysis.</description>
        <time_frame>Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose</time_frame>
        <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had Cmax data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189 in Schizophrenia Participants</title>
          <description>Cmax was defined as the maximum concentration of MK-8189 observed in plasma. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Cmax following MK-8189 administration. As specified by the protocol, Cmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Cmax analysis.</description>
          <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had Cmax data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="29.9"/>
                    <measurement group_id="O6" value="63.6" spread="27.5"/>
                    <measurement group_id="O7" value="165" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="60.7"/>
                    <measurement group_id="O6" value="90.6" spread="41.7"/>
                    <measurement group_id="O7" value="277" spread="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="212" spread="52.0"/>
                    <measurement group_id="O7" value="210" spread="29.8"/>
                    <measurement group_id="O8" value="518" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="285" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O3" value="472" spread="40.8"/>
                    <measurement group_id="O8" value="409" spread="28.8"/>
                    <measurement group_id="O9" value="718" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="11"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="209" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O4" value="628" spread="28.5"/>
                    <measurement group_id="O9" value="638" spread="34.8"/>
                    <measurement group_id="O10" value="1050" spread="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Post-dose at Which the Maximum Plasma Concentration (Tmax) of MK-8189 Was Observed in Schizophrenia Participants</title>
        <description>Tmax was defined as the time required post dose to reach a maximum plasma concentration of MK-8189. It was estimated as the actual sampling time at the highest MK-8189 plasma concentration. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Tmax following MK-8189 administration. As specified by the protocol, Tmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Tmax analysis.</description>
        <time_frame>Day 1 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post-dose; Days 4, 8, 11 pre-dose and 6, 10, 16, 24 hours post-dose; Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose</time_frame>
        <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had Tmax data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Time Post-dose at Which the Maximum Plasma Concentration (Tmax) of MK-8189 Was Observed in Schizophrenia Participants</title>
          <description>Tmax was defined as the time required post dose to reach a maximum plasma concentration of MK-8189. It was estimated as the actual sampling time at the highest MK-8189 plasma concentration. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points to estimate Tmax following MK-8189 administration. As specified by the protocol, Tmax was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, some time points were not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from Tmax analysis.</description>
          <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had Tmax data available for Days 1, 4, 8, 11, or 14. Due to differing dosing schedules, some time points were not applicable for some arms (shown by 0 participants analyzed). Per protocol, healthy participants (Part 3) and placebo arms were excluded.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="23.83"/>
                    <measurement group_id="O6" value="23.83" lower_limit="10.10" upper_limit="25.27"/>
                    <measurement group_id="O7" value="23.83" lower_limit="16" upper_limit="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="23.87"/>
                    <measurement group_id="O6" value="23.83" lower_limit="6" upper_limit="23.92"/>
                    <measurement group_id="O7" value="8" lower_limit="0" upper_limit="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="23.98"/>
                    <measurement group_id="O7" value="16" lower_limit="0" upper_limit="23.83"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10" lower_limit="NA" upper_limit="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O3" value="10.03" lower_limit="10" upper_limit="23.83"/>
                    <measurement group_id="O8" value="16" lower_limit="0" upper_limit="23.83"/>
                    <measurement group_id="O9" value="16" lower_limit="6" upper_limit="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="11"/>
                    <count group_id="O10" value="6"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="0"/>
                    <count group_id="O16" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="20" lower_limit="NA" upper_limit="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O4" value="16" lower_limit="6" upper_limit="24"/>
                    <measurement group_id="O9" value="12" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O10" value="8" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent t1/2) in Schizophrenia Participants on Day 14</title>
        <description>t1/2 was defined as the time required to divide the MK-8189 plasma concentration by half after reaching pseudo-equilibrium. At least three quantifiable post-Cmax, terminal phase concentrations collected were used to calculate the apparent t1/2. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points on Day 14 to estimate t1/2 following MK-8189 administration. As specified by the protocol, t1/2 was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, the Day 14 timepoint was not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from t1/2 analysis.</description>
        <time_frame>Day 14 pre-dose and 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 hours post-dose</time_frame>
        <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had t1/2 data available for Day 14. Due to differing dosing schedules, some time points were not applicable for some arms/doses (indicated by zero participants analyzed). Per protocol healthy participants (Part 3) and placebo arms were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent t1/2) in Schizophrenia Participants on Day 14</title>
          <description>t1/2 was defined as the time required to divide the MK-8189 plasma concentration by half after reaching pseudo-equilibrium. At least three quantifiable post-Cmax, terminal phase concentrations collected were used to calculate the apparent t1/2. Blood samples were collected pre-dose and up to 48 hours post-dose at multiple time points on Day 14 to estimate t1/2 following MK-8189 administration. As specified by the protocol, t1/2 was analyzed by part, dose and dosing schedule. Due to differing dosing schedules, the Day 14 timepoint was not applicable for certain arms/doses as indicated by zero participants analyzed entered in the table. Per protocol, healthy participants (Part 3) and participants receiving placebo were excluded from t1/2 analysis.</description>
          <population>Schizophrenia participants who received ≥1 dose of MK-8189, complied with the protocol and had t1/2 data available for Day 14. Due to differing dosing schedules, some time points were not applicable for some arms/doses (indicated by zero participants analyzed). Per protocol healthy participants (Part 3) and placebo arms were excluded.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9.14" spread="NA">Measure of dispersion could not be estimated due to low number of participants analyzed</measurement>
                    <measurement group_id="O4" value="8.38" spread="37.8"/>
                    <measurement group_id="O9" value="8.86" spread="37.4"/>
                    <measurement group_id="O10" value="10.4" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced at least one AE were reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>All participants who received as least one dose of the investigational drug. Per protocol, safety was assessed by part and dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced at least one AE were reported.</description>
          <population>All participants who received as least one dose of the investigational drug. Per protocol, safety was assessed by part and dose.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="17"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="10"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="10"/>
                <count group_id="O15" value="9"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinue From Study Treatment Due to an AE</title>
        <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE were reported.</description>
        <time_frame>Up to Day 14</time_frame>
        <population>All participants who received as least one dose of the investigational drug. Per protocol, safety was assessed by part and dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O10">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
          </group>
          <group group_id="O11">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O15">
            <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
            <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
          </group>
          <group group_id="O16">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinue From Study Treatment Due to an AE</title>
          <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE were reported.</description>
          <population>All participants who received as least one dose of the investigational drug. Per protocol, safety was assessed by part and dose.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="17"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="10"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="10"/>
                <count group_id="O15" value="9"/>
                <count group_id="O16" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 13 in Mismatched Negativity (MMN) Peak Amplitude in Monotherapy MK-8189-treated Schizophrenia Participants</title>
        <description>MMN is a response to deviant tone (stimuli) measured in electroencephalogram (EEG) signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; this difference at peak waveform is MMN peak amplitude. Schizophrenic participants show reduced response to deviant stimuli. Peak amplitude change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.</description>
        <time_frame>Baseline and Day 13</time_frame>
        <population>Per protocol, MMN analyses were planned and executed in all Schizophrenia participants receiving MK-8189 monotherapy (irrespective of dosing schedule) with EEG electrode data available. Per protocol MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-12 mg: Schizophrenic</title>
            <description>Participants received MK-8189 escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14 or alternatively 2 mg QD Days 1-4 and 4 mg QD Days 5-14</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy</title>
            <description>Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
          </group>
          <group group_id="O7">
            <title>Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy</title>
            <description>Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14</description>
          </group>
          <group group_id="O8">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 13 in Mismatched Negativity (MMN) Peak Amplitude in Monotherapy MK-8189-treated Schizophrenia Participants</title>
          <description>MMN is a response to deviant tone (stimuli) measured in electroencephalogram (EEG) signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; this difference at peak waveform is MMN peak amplitude. Schizophrenic participants show reduced response to deviant stimuli. Peak amplitude change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.</description>
          <population>Per protocol, MMN analyses were planned and executed in all Schizophrenia participants receiving MK-8189 monotherapy (irrespective of dosing schedule) with EEG electrode data available. Per protocol MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3) and all placebo-treated participants were excluded.</population>
          <units>µV</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.959" lower_limit="-0.218" upper_limit="2.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.812" lower_limit="-0.169" upper_limit="1.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.170" lower_limit="-0.203" upper_limit="2.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.547" lower_limit="0.171" upper_limit="2.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.240" lower_limit="-0.006" upper_limit="2.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.616" lower_limit="-0.471" upper_limit="1.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.488" lower_limit="-1.113" upper_limit="2.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fp1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.779" lower_limit="-0.586" upper_limit="2.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fp2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.103" lower_limit="-0.480" upper_limit="2.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.462" lower_limit="0.256" upper_limit="2.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.099" lower_limit="-1.548" upper_limit="1.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" lower_limit="-1.186" upper_limit="1.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.236" lower_limit="-1.188" upper_limit="1.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" lower_limit="-1.233" upper_limit="1.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.599" lower_limit="-0.675" upper_limit="1.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.018" lower_limit="-1.924" upper_limit="3.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.306" lower_limit="-2.667" upper_limit="3.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.260" lower_limit="-3.475" upper_limit="2.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178" lower_limit="-2.378" upper_limit="2.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 13 in Mismatched Negativity (MMN) Area Under Curve (AUC) in Monotherapy MK-8189-treated Schizophrenia Participants</title>
        <description>MMN is a response to deviant tone (stimuli) measured in EEG signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; AUC was measured as the product of MMN amplitude and time. Schizophrenic participants show reduced response to deviant stimuli. AUC change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.</description>
        <time_frame>Baseline and Day 13</time_frame>
        <population>Per protocol, MMN analyses were planned and executed in all Schizophrenia participants receiving MK-8189 monotherapy (irrespective of dosing schedule) with EEG electrode data available. Per protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2-12 mg: Schizophrenic</title>
            <description>Participants received MK-8189 escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14 or alternatively 2 mg QD Days 1-4 and 4 mg QD Days 5-14</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 2-12 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Panel C MK-8189 Add-on Therapy 4-16 mg: Schizophrenic</title>
            <description>Participants with Schizophrenia received add-on therapy of MK-8189 in escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 12 mg QD Days 9-11, and 16 mg QD Days 12-14</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
            <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
          </group>
          <group group_id="O6">
            <title>Part 3 Panel D MK-8189 Monotherapy 2-12 mg: Healthy</title>
            <description>Healthy participants received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 12 mg QD Days 12-14</description>
          </group>
          <group group_id="O7">
            <title>Part 3 Panel D MK-8189 Monotherapy 2-8 mg: Healthy</title>
            <description>Healthy participant received monotherapy of MK-8189 in escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, and 8 mg QD days 9-14</description>
          </group>
          <group group_id="O8">
            <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
            <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 13 in Mismatched Negativity (MMN) Area Under Curve (AUC) in Monotherapy MK-8189-treated Schizophrenia Participants</title>
          <description>MMN is a response to deviant tone (stimuli) measured in EEG signals. Difference in deviant EEG waveform amplitude from standard amplitude over time indicates MMN; AUC was measured as the product of MMN amplitude and time. Schizophrenic participants show reduced response to deviant stimuli. AUC change from baseline (Day -1) to Day 13 was reported. A higher change indicates improved response to deviant stimuli. Scalp EEG signals were collected using a standard system array of 19 electrodes denoted by nomenclature of scalp placement: C3, C4, Cz, F3, F4, F7, F8, Fp1, Fp2, Fz, O1, O2, P3, P4, Pz, T3, T4, T5, T6. As specified by the protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded from MMN analyses. Per protocol, MMN analyses were planned and executed in all schizophrenia participants receiving MK-8189 monotherapy, irrespective of different dosing schedules.</description>
          <population>Per protocol, MMN analyses were planned and executed in all Schizophrenia participants receiving MK-8189 monotherapy (irrespective of dosing schedule) with EEG electrode data available. Per protocol, MK-8189 add-on therapy schizophrenia participants (Part 2), healthy participants (Part 3), and all placebo-treated participants were excluded.</population>
          <units>µV*msec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.162" lower_limit="-25.187" upper_limit="16.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.800" lower_limit="-12.255" upper_limit="17.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.813" lower_limit="-19.664" upper_limit="25.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.277" lower_limit="-12.012" upper_limit="24.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.814" lower_limit="-5.671" upper_limit="25.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.582" lower_limit="-8.968" upper_limit="7.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.817" lower_limit="-3.836" upper_limit="21.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fp1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.390" lower_limit="-7.696" upper_limit="24.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fp2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.483" lower_limit="-9.046" upper_limit="32.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.880" lower_limit="-14.368" upper_limit="30.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.011" lower_limit="-23.898" upper_limit="17.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.261" lower_limit="-24.940" upper_limit="4.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.560" lower_limit="-34.188" upper_limit="15.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.154" lower_limit="-29.863" upper_limit="11.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.019" lower_limit="-36.607" upper_limit="16.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.594" lower_limit="-48.553" upper_limit="17.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.341" lower_limit="-23.264" upper_limit="16.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.394" lower_limit="-47.983" upper_limit="9.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.686" lower_limit="-39.170" upper_limit="13.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 28; all-cause mortality was assessed for up to ~9 months</time_frame>
      <desc>Safety was assessed by part and dose, in all participants who received as least one dose of the investigational drug. Post Study AEs were pooled across the arms in each part of the study. AEs that occurred beyond 14 days of dosing were considered Post Study AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 2 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
        </group>
        <group group_id="E2">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 4 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 14, based on participant tolerability</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 8 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 8 mg QD starting on day 9 and continuing up to Day 11, based on participant tolerability</description>
        </group>
        <group group_id="E4">
          <title>Part 1 Panel A &amp; B MK-8189 Monotherapy 12 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
        </group>
        <group group_id="E5">
          <title>Part 1 Panel A &amp; B Placebo Monotherapy: Schizophrenic</title>
          <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
        </group>
        <group group_id="E6">
          <title>Part 1 Panel A &amp; B Post Study: Schizophrenic</title>
          <description>Participants with Schizophrenia who received monotherapy MK-8189 or matching placebo during the treatment period, were followed for safety during the post study period</description>
        </group>
        <group group_id="E7">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 2 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
        </group>
        <group group_id="E8">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 4 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 4 mg QD starting on Day 1 and continuing up to Day 8, based on participant tolerability</description>
        </group>
        <group group_id="E9">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 8 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 8 mg QD starting on Day 5 and continuing up to Day 11, based on participant tolerability</description>
        </group>
        <group group_id="E10">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 12 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 12 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
        </group>
        <group group_id="E11">
          <title>Part 2 Panel C MK-8189 Add-on Therapy 16 mg: Schizophrenic</title>
          <description>Participants with Schizophrenia received add-on therapy MK-8189 oral dose of 16 mg QD starting on Day 12 and continuing up to day 14, based on participant tolerability</description>
        </group>
        <group group_id="E12">
          <title>Part 2 Panel C Placebo Add-on Therapy: Schizophrenic</title>
          <description>Participants with Schizophrenia received dose-matched placebo to MK-8189 add-on therapy on Days 1-14</description>
        </group>
        <group group_id="E13">
          <title>Part 2 Panel C Post Study: Schizophrenic</title>
          <description>Participants with Schizophrenia who received add-on therapy MK-8189 or matching placebo during the treatment period, were followed for safety during the post study period</description>
        </group>
        <group group_id="E14">
          <title>Part 3 Panel D MK-8189 Monotherapy 2 mg: Healthy</title>
          <description>Healthy participants received monotherapy MK-8189 oral dose of 2 mg QD starting on Day 1 and continuing up to Day 4, based on participant tolerability</description>
        </group>
        <group group_id="E15">
          <title>Part 3 Panel D MK-8189 Monotherapy 4 mg: Healthy</title>
          <description>Healthy participants received monotherapy MK-8189 oral dose of 4 mg QD starting on Day 5 and continuing up to Day 8, based on participant tolerability</description>
        </group>
        <group group_id="E16">
          <title>Part 3 Panel D MK-8189 Monotherapy 8 mg: Healthy</title>
          <description>Healthy participants received monotherapy MK-8189 oral dose of 8 mg QD starting on Day 9 and continuing up to Day 14, based on participant tolerability</description>
        </group>
        <group group_id="E17">
          <title>Part 3 Panel D MK-8189 Monotherapy 12 mg: Healthy</title>
          <description>Healthy participants received monotherapy MK-8189 oral dose of 12 mg QD starting on Day 12 and continuing up to Day 14, based on participant tolerability</description>
        </group>
        <group group_id="E18">
          <title>Part 3 Panel D Placebo Monotherapy: Healthy</title>
          <description>Healthy participants received dose-matched placebo to MK-8189 monotherapy on Days 1-14</description>
        </group>
        <group group_id="E19">
          <title>Part 1 Panel D Post Study: Healthy</title>
          <description>Healthy participants who received monotherapy MK-8189 or matching placebo during the treatment period, were followed for safety during the post study period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oromandibular dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sleep paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spasmodic dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anhedonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depersonalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Derealisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were some missing event markers in EEG recordings during data collection, these were imputed for the MMN analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

